Fosdenopterin hydrobromide for the treatment of patients molybdenum cofactor deficiency type A

NICE

19 September 2024 - The Department of Health and Social Care has NICE to produce guidance on the use of fosdenopterin hydrobromide in the NHS in England.

For the time being, fosdenopterin hydrobromide is not recommended for the treatment of patients of all ages with molybdenum cofactor deficiency type A.

Read NICE draft guidance consultation

Michael Wonder

Posted by:

Michael Wonder